191 related articles for article (PubMed ID: 22398597)
61. Cystic fibrosis in an era of genomically guided therapy.
Barrett PM; Alagely A; Topol EJ
Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
[TBL] [Abstract][Full Text] [Related]
62. Transformative mutation specific pharmacotherapy for cystic fibrosis.
Sanders DB; Farrell PM
BMJ; 2012 Jan; 344():e79. PubMed ID: 22232540
[No Abstract] [Full Text] [Related]
63. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
Desch M
Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
[No Abstract] [Full Text] [Related]
64. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
65. Cystic fibrosis in the era of genomic medicine.
Milla CE
Curr Opin Pediatr; 2013 Jun; 25(3):323-8. PubMed ID: 23652683
[TBL] [Abstract][Full Text] [Related]
66. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.
Cohen D; Raftery J
BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379
[No Abstract] [Full Text] [Related]
67. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Mayer M
Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
[No Abstract] [Full Text] [Related]
68. Ivacaftor (Kalydeco) for cystic fibrosis.
Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233
[No Abstract] [Full Text] [Related]
69. Cystic fibrosis--what are the prospects for a cure?
Kumar S; Tana A; Shankar A
Eur J Intern Med; 2014 Nov; 25(9):803-7. PubMed ID: 25447947
[TBL] [Abstract][Full Text] [Related]
70. Ivacaftor, vismodegib, and ingenol mebutate.
Hussar DA; Eckel SP
J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984
[No Abstract] [Full Text] [Related]
71. Straight talk with... Robert Beall. Interviewed by Elie Dolgin.
Beall R
Nat Med; 2012 Mar; 18(3):335. PubMed ID: 22395687
[No Abstract] [Full Text] [Related]
72. Targeting a cystic fibrosis mutation opens door for personalized treatment.
Morrow T
Manag Care; 2012 Apr; 21(4):53-4. PubMed ID: 22590787
[No Abstract] [Full Text] [Related]
73. Another Beginning for Cystic Fibrosis Therapy.
Davis PB
N Engl J Med; 2015 Jul; 373(3):274-6. PubMed ID: 25981385
[No Abstract] [Full Text] [Related]
74. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.
Hayes D; Warren PS; McCoy KS; Sheikh SI
J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481
[TBL] [Abstract][Full Text] [Related]
75. A new chapter in therapy for cystic fibrosis.
Bilton D
Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158
[No Abstract] [Full Text] [Related]
76. The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective.
Saynor ZL; Barker AR; Oades PJ; Williams CA
Pediatr Phys Ther; 2014; 26(4):454-61. PubMed ID: 25251804
[TBL] [Abstract][Full Text] [Related]
77. Cystic fibrosis: bridging the treatment gap in early childhood.
Davies JC
Lancet Respir Med; 2013 Aug; 1(6):433-4. PubMed ID: 24429232
[No Abstract] [Full Text] [Related]
78. Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma.
Jiménez-Gómez M; Díaz Campos RM; Diab Cáceres L
Arch Bronconeumol; 2023 Aug; 59(8):512-513. PubMed ID: 37127448
[No Abstract] [Full Text] [Related]
79. Personalized medicine comes to cystic fibrosis.
Am J Med Genet A; 2012 Feb; 158A(2):viii-ix. PubMed ID: 22266959
[No Abstract] [Full Text] [Related]
80. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy.
Hayes D; McCoy KS; Sheikh SI
Am J Respir Crit Care Med; 2014 Sep; 190(5):590-1. PubMed ID: 25171312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
